Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;12(1):20-26.
doi: 10.1016/j.prnil.2023.10.003. Epub 2023 Nov 2.

Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study

Alicia López-Abad  1 , Miguel Ramírez Backhaus  2 , Gerardo Server Gómez  3 , Enrique Cao Avellaneda  1 , Cristóbal Moreno Alarcón  1 , Pedro López Cubillana  1 , Pablo Yago Giménez  1 , Pedro de Pablos Rodríguez  2 , María J Juan Fita  2 , Miguel Á Climent Durán  2 , Iris Guardiola Ruiz  3 , Natalia Vidal Crespo  3 , Miriam Artés Artés  3 , Raúl Montoya Chinchilla  3 , Juan Moreno Avilés  3 , Pablo L Guzmán Martínez-Valls  1 , Pedro Á López González  1
Affiliations

Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study

Alicia López-Abad et al. Prostate Int. 2024 Mar.

Abstract

Background: Metastatic hormone-sensitive prostate cancer (mHSPC) treatment has changed drastically during the last years with the emergence of androgen receptor-targeted agents (ARTAs). ARTA combined with androgen deprivation therapy has demonstrated better oncological and survival outcomes in these patients. However, the optimal choice among different ARTAs remains uncertain due to their analogous efficacy.

Objectives: The objective of this study was to describe prostate-specific antigen (PSA) response and oncological outcomes of patients with mHSPC treated with apalutamide.

Material and methods: Medical records from three different hospitals in Spain were used to conduct this study. Patients diagnosed with mHSPC and under apalutamide treatment were included between March 2021 and January 2023. Data regarding PSA response, overall survival (OS), and radiographic progression-free survival (rPFS) were collected and stratified by metastasis volume, timing, and stating.

Results: 193 patients were included; 34.2% of patients were de novo mHSPC, and the majority was classified as m1b. The 18-month OS and rPFS were 92.5% and 88.9%, respectively. Patients with PSA levels ≤0.2 ng/ml showcased an 18-month OS rate of 98.7%, contrasting with 65.3% for those with PSA >0.2 ng/ml. Similar trends emerged for rPFS (97.4% and 53.7%, respectively). When differentiating between low-volume and high-volume metastasis, the OS rate stood at 98.4% and 80.7%, respectively, while the rPFS rates were 93% and 81.6%, respectively. No significant differences were found between groups stratified by metastasis timing.

Conclusion: This real-world study on patients with mHSPC treated with apalutamide plus androgen deprivation therapy revealed robust oncological outcomes, aligning with the emerging evidence. The study's hallmark finding highlights the significance of rapid and deep PSA response as a predictor of improved oncological and survival outcomes.

Keywords: De novo; Metastatic hormone-sensitive prostate cancer; Metastatic volume; Prostate cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overview of the main adverse events observed in the included patients.
Figure 2
Figure 2
PSA levels graphics showing the 50% PSA reduction, 90% PSA reduction, and PSA ≤0.2 ng/ml achieved in our cohort, stratified by metastasis volume (high-volume and low-volume) and time of presentation (synchronous and metachronous). Abbreviation: PSA = prostrate-specific antigen.
Figure 3
Figure 3
A. Kaplan–Meier Survival Curve for Overall Survival (OS) by Metastasis Volume. B. Kaplan–Meier Survival Curve for radiographic progression-free survival (rPFS) by Metastasis Volume. C. Kaplan–Meier Survival Curve for OS by PSA levels. D. Kaplan–Meier Survival Curve for rPFS by PSA levels.
Figure 4
Figure 4
Kaplan Meir Survival Curve for OS (A) and rPFS (B) by time of metastasis. Abbreviations: OS = overall survival; PSA = prostrate-specific antigen.
See this image and copyright information in PMC

References

    1. International Agency for Research on Cancer . Globocan; 2022. World Health Organization.https://gco.iarc.fr/ [Internet]. [cited 2023 May 21]. Available from:
    1. Sociedad Española de Oncología Médica . 2021. Las cifras del cáncer en España.https://seom.org/images/Cifras_del_cancer_en_Espnaha_2021.pdf [Internet]. [cited 2023 May 21]. Available from: chrome-extension.
    1. Cózar J.M., Miñana B., Gómez-Veiga F., Rodríguez-Antolín A., Villavicencio H., Cantalapiedra A., et al. Registro nacional de cáncer de próstata 2010 en España. Actas Urol Esp. 2013;37(1):12–19. - PubMed
    1. Patrikidou A., Loriot Y., Eymard J.C., Albiges L., Massard C., Ileana E., et al. Who dies from prostate cancer? Prostate Cancer Prostatic Dis. 2014;17(4):348–352. - PubMed
    1. James N.D., Spears M.R., Clarke N.W., Dearnaley D.P., De Bono J.S., Gale J., et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019) Eur Urol. 2015;67(6):1028–1038. - PubMed